Subclinical thyroid condition associated with increased cardiovascular mortality

Having high thyroid activity, and even "high-normal" levels, is a significant risk factor for cardiovascular and all-cause mortality, according to work which has received an award at the European Congress of Endocrinology in Copenhagen.

Subclinical hyperthyroidism is diagnosed when the levels of (TSH) are low, but the free hormones (T4) and triiodothyronine (T3) are within normal range. You may have no symptoms at all, or symptoms such as the classical symptoms of an overactive thyroid - weight loss, higher blood pressure, nervousness, etc. These symptoms may be mild. TSH is produced as a signal from the pituitary gland to produce more , so low TSH implies that the body sees that your thyroid is tending to overactivity.

Now a group of Danish researchers led by Dr Christian Selmer studied the thyroid test results of more than half a million individuals who underwent thyroid testing in Copenhagen between 2000 and 2009. They found that those with subclinical hyperthyroidism were significantly more likely to die from cardiovascular disease. They also found that even patients having only slightly elevated thyroid activity, but still within the range which would be considered normal, showed a tendency to higher cardiovascular and other mortality.

The group looked at the results of 574,595 patients who had undergone testing. 95.9% of these patients showed normal . However 6,264 patients exhibited subclinical hyperthyroidism, 706 of whom subsequently died of various causes. According to Christian Selmer:

"According to our work, 15% of deaths in the subclinical group could be attributed to the condition."

Even those at the high end of the normal range showed an increase in mortality. There were 13,434 patients in this range. 1,013 of these died of various causes, with 17% of the deaths associated with the thyroid condition. The authors emphasised that it is difficult to put exact numbers on the actual excess deaths caused by the condition for a variety of reasons. They state that they do not know if treatment of these conditions will in fact eliminate these excess deaths. This will be the goal of further studies.

Dr Christian Selmer, Research Fellow at Gentofte University Hospital, Denmark, and a winner of a Young Investigator Award at the European Congress of Endocrinology, said:

"Let's keep this in context. Of the more than half million people who were tested, 50,612 subsequently died from all causes. According to our figures, this includes around 278 deaths which can be attributed to the subclinical thyroid or "high-normal" conditions we looked at, but it is important to remember that this is a calculated figure; we can't point to an individual and say he or she died because of the condition, and is one of many . Nevertheless, this needs to be taken seriously. I think that the take-home message is that if a person has a family history with any thyroid problem, or has any signs of thyroid problems, then they should go for a check-up. More than that, their family doctors need to be aware that any sign of abnormality can affect cardiovascular health, and they should act accordingly".

More information: www.endocrine-abstracts.org/ea/0032/default.htm

Subclinical hyperthyroidism and risk of cardiovascular and all-cause mortality, Christian Selmer, Jonas Olesen, Jesper Madsen, Jens Faber, Peter Hansen, Ole Pedersen, Morten Hansen, Christian Torp-Pedersen, Gunnar Gislason

Background: It is still discussed if subclinical hyperthyroidism and "high-normal" thyroid function are risk-factors for cardiovascular mortality.
Objectives: To examine the risk of cardiovascular and all-cause mortality in relation to subclinical hyperthyroidism.
Methods: Patients consulting their general practitioner from 2000–2009 in Copenhagen, Denmark, who underwent thyroid blood tests, were identified by individual-level linkage of nationwide registries. Patients with a history of thyroid disease or related medication were excluded. Risk of cardiovascular mortality was analyzed using Kaplan-Meier curves and Poisson regression models were applied to estimate Incidence Rate Ratios (IRR).
Results: Of 574,595 included individuals (mean age 48.7 years [SD ±18.3]; 39.1% males) 550,927 (95.9%) were euthyroid, 1,603 (0.3%) had overt hypothyroidism, 11,834 (2.1%) subclinical hypothyroidism, 3,967 (0.7%) overt hyperthyroidism and 6,264 (1.1%) subclinical hyperthyroidism. Increased risk of cardiovascular mortality was found in two levels of subclinical hyperthyroidism (TSH <0.1, 0.1–0.2 mU/L and normal free thyroixine): IRR 1.24 [95% CI: 1.09–1.41], IRR 1.21 [1.09–1.34] and in "high-normal" levels of euthyroidism (TSH 0.2–0.4 mU/L): IRR 1.21 [1.13–1.29].
Conclusions: Subclinical hyperthyroidism and "high-normal" thyroid function are significant risk-factors for cardiovascular and all-cause mortality.

Provided by European Congress of Endocrinology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Thyroid problems linked to irregular heart rhythm

Nov 28, 2012

People with an overactive thyroid gland (hyperthyroidism) carry a greater risk of developing irregular heart rhythm (known as atrial fibrillation) than those with normal thyroid function, finds a study published on BMJ today. ...

Hip fractures and thyroid disease linked in study

Nov 30, 2010

New research from UC Davis Health System finds that older men with subclinical thyroid dysfunction have an increased risk of suffering hip fractures and suggests that screening and treatment for thyroid dysfunction in its ...

Low thyroid function common in chronic kidney disease

Jun 11, 2008

Many patients with chronic kidney disease (CKD) have mild reductions in thyroid function, or subclinical hypothyroidism—a condition that becomes more common as kidney function declines, according to a study in the September ...

Recommended for you

Popular prostate cancer therapy may be harmful

2 hours ago

A widely used treatment for prostate cancer may cause more harm than good for some patients, according to Dr. Oliver Sartor, medical director of the Tulane Cancer Center.

User comments